Search results
Duchenne Muscular Dystrophy (DMD) Treatment
Verywell Health via Yahoo News· 4 days agoInsights Into Treatment Advancements Medically reviewed by Nicholas R. Metrus, MDMedically reviewed by Nicholas R. Metrus, MD Duchenne muscular
Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again
Investor's Business Daily· 1 day agoDyne studied drugs it calls DYNE-101 and DYNE-251 in patients with myotonic dystrophy type 1 and ...
European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug
BioPharma Dive via Yahoo Finance· 2 days agoRather than endorse the recommendation of the EMA, the commission called for a new review for...
Jar of Hope staging unique race to save kids
Staten Island Advance· 7 days agoAll proceeds will go toward funding a cure for Duchenne muscular dystrophy. “We’ve taken great pains to plan unique events over the years ...
Why Is Dyne Therapeutics Stock Soaring On Monday?
Benzinga via Yahoo Finance· 1 day agoEarlier this year, Dyne Therapeutics released initial clinical data from both trials. In the ACHIEVE trial, patients in the 5.4 mg/kg Q8W cohort had...
Barclays cuts Solid Biosciences target to $18 from $21 By Investing.com
Investing.com· 6 days agoOn Thursday, Barclays adjusted its outlook on Solid Biosciences (NASDAQ:SLDB), a company...
Dyne shares jump on trial data for muscle disease drugs
BioPharma Dive via Yahoo Finance· 2 days agoUpdated study results for the biotech’s medicines for myotonic dystrophy Type 1 and Duchenne ...
Biotech Soars As Its Biggest Drug 'Lives To Fight Another Day'
Investor's Business Daily· 2 days agoTranslarna has a conditional approval in Europe to treat patients with a muscle-wasting disease...
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Zacks via Yahoo Finance· 15 hours agoDyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage...
Dyne Therapeutics Discloses Positive Trial Data for DYNE-101, DYNE-251 Treatments
Market Watch· 2 days agoBy Denny Jacob Dyne Therapeutics disclosed positive clinical data from trials on treatments for patients with myotonic dystrophy type 1 and Duchenne muscular...
